友芝友生物製藥

WUHAN YZY BIOPHARMA CO., LTD.
武漢友芝友生物製藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2496)

VOLUNTARY ANNOUNCEMENT

THE FIRST PATIENT ENROLLED IN PHASE II CLINICAL TRIAL OF M701, A BISPECIFIC ANTIBODY FOR TREATMENT OF MALIGNANT PLEURAL EFFUSION

This announcement is made by Wuhan YZY Biopharma Co., Ltd. (the "**Company**") on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business updates of the Company.

The board of directors of the Company (the "**Board**") is pleased to announce that, the first patient has recently been enrolled in a Phase II clinical trial of M701, a bispecific antibody ("**BsAb**") drug candidate dually targeting epithelial cell adhesion molecule ("**EpCAM**") and cluster of differentiation 3 ("**CD3**") independently developed by the Company, for treatment of malignant pleural effusion (the "**MPE Study**"). The MPE Study aims to investigate the efficacy and safety of M701 through intrapleural infusion compared to thoracentesis and/or thoracic chemotherapy in patients with malignant pleural effusion ("**MPE**") caused by non-small cell lung cancer.

ABOUT MALIGNANT PLEURAL EFFUSION

MPE is a complication commonly found in patients with advanced tumors, such as lung cancer and breast cancer. It is caused by tumor cells invading tissues and triggering the release of negative factors, leading to endothelial cell dysfunction and increased exudates. Tumor cells obstruct lymphatic vessels, resulting in fluid accumulation. MPE not only causes symptoms that significantly impact patients' quality of life, such as chest tightness, dyspnea, chest pain, nausea and vomiting, but also affects physicians' evaluation of the efficacy of current systemic therapies. There is still a lack of clinical drugs for MPE in China. In European countries and America, intrapleural administration of talcum powder is recommended for MPE to promote pleural adhesion, thereby inhibiting the production of exudates. However, this approach has severe side effects. Safer and more effective innovative drugs are urgently needed for patients.

ABOUT M701

M701, a BsAb, is an innovative Category I biological drug that can target both EpCAM (as the target on tumor cells) and CD3 (as the immune T cell activation target). Its main mechanism of action involves binding to both tumor cells and immune T cells through these targets, thereby activating T cells to kill tumor cells. Therefore, intrapleural infusion of M701 can activate immune cells to selectively eliminate and suppress tumor cells in the chest cavity, thereby achieving the effect of inhibiting pleural effusion. In the Phase Ib clinical trial conducted by the Company, intrapleural infusion of M701 demonstrated good safety and efficacy for MPE.

ABOUT THE COMPANY

We are a biotechnology company dedicated to developing BsAb-based therapies for treating cancer-associated complications, cancer and age-related ophthalmologic diseases. In particular, we have been focusing on developing the T cell-engaging BsAb (including M701), and the tumor microenvironment (TME)-targeted BsAbs, including Y101D and Y332. Our Core Product, M701, is a recombinant BsAb that targets cancer cells expressing human EpCAM and T cells expressing human CD3. We are primarily developing M701 for palliative care for malignant ascites and MPE, which are severe complications of cancer characterized by the accumulation of fluids in the abdominal or chest cavity of cancer patients.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that M701 will ultimately be successfully developed and marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Wuhan YZY Biopharma Co., Ltd.
Dr. Zhou Pengfei
Chairman of the Board, Executive Director and Chief Executive Officer

Wuhan, PRC, March 26, 2024

As of the date of this announcement, the Board comprises Dr. Zhou Pengfei as executive director, Dr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu, Ms. Liang Qian, Dr. Liu Dan, Dr. Guo Hongwei and Mr. Xie Shouwu as non-executive directors; and Dr. Cheng Bin, Dr. Dai Weiguo, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive directors.